Nabi Biopharmaceuticals Enters Clinical Initiative With US Military to Advance PentaStaph(tm)
Published: Dec 17, 2008
ROCKVILLE, Md., Dec. 17, 2008 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) has entered into a Cooperative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU), an institution of higher learning within the Department of Defense (DoD), an agency of the United States Government, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), a private, not-for-profit organization that supports medical research and education at the university and the military medical community. The overall goal of the CRADA, which will involve researchers from USU's Infectious Disease Clinical Research Program (IDCRP) and Nabi, is to develop a licensed pentavalent S. aureus vaccine to prevent skin and soft tissue infection. The IDCRP has the mandate to design, conduct and publish collaborative clinical Infectious Disease research of importance to the DoD (and, also, the National Institute of Allergy and Infectious Diseases (NIAID)) through an effective research network that rapidly responds to evolving Infectious Disease threats.